Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy
Acta Histochemica · 2024
DOI: 10.1016/j.acthis.2024.152183 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Histochemica, 2024. Verfasst von Suncica Kapor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Clinical, and Hospital Center "Dr. Dragiša Mišović-Dedinje,", Heroja Milana Tepića 1, Belgrade 11020, Serbia. Hauptthemen laut MEDLINE: Myeloid-Derived Suppressor Cells, Immunotherapy, Tumor Microenvironment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 164 Literaturangaben. Gefördert von: Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja.
Abstract (Originalsprache)
Myeloid malignancies stem from a modified hematopoietic stem cell and predominantly include acute myeloid leukemia, myelodysplastic neoplasms, myeloproliferative malignancies, and chronic myelomonocytic leukemia. Myeloid-derived suppressor cells (MDSCs) exhibit immunoregulatory properties by governing the innate and adaptive immune systems, creating a permissive and supportive environment for neoplasm growth. This review examines the key characteristics of MDSCs in myeloid malignancies, highlighting that an increased MDSC count corresponds to heightened immunosuppressive capabilities, fostering an immune-tolerant neoplasm microenvironment. Also, this review analyzes and describes the potential of combined cancer therapies, focusing on targeting MDSC generation, expansion, and their inherent immunosuppressive activities to enhance the efficacy of current cancer immunotherapies. A comprehensive understanding of the implications of myeloid malignancies may enhance the exploration of immunotherapeutic strategies for their potential application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Clinical, and Hospital Center "Dr. Dragiša Mišović-Dedinje,", Heroja Milana Tepića 1, Belgrade 11020, Serbia.
- Department of Hematology, Clinical, and Hospital Center "Dr. Dragiša Mišović-Dedinje,", Heroja Milana Tepića 1, Belgrade 11020, Serbia; Faculty of Medicine, University of Belgrade, Dr. Subotića Starijeg 8, Belgrade 1100…
- Molecular Oncology group, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Dr. Subotica 4, POB 102, Belgrade 11129, Serbia; Centro Integrativo de Biología y Química A…
Förderung
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja
Zitieren
APA
Kapor, S., Radojković, M., & Santibanez, J. F. (2024). Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy. Acta Histochemica. https://doi.org/10.1016/j.acthis.2024.152183
Vancouver
Kapor S, Radojković M, Santibanez JF. Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy. Acta Histochemica. 2024. doi:10.1016/j.acthis.2024.152183
BibTeX
@article{Kapor2024,
author = {Kapor, Suncica and Radojković, Milica and Santibanez, Juan F},
title = {Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy},
journal = {Acta Histochemica},
year = {2024},
doi = {10.1016/j.acthis.2024.152183}
}
EUVIMED